Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc.

We recently compiled a list of the 10 Firms Shine Amid Market Slump. In this article, we are going to take a look at where ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Tempus AI’s diagnostic platform drives growth, but US healthcare reimbursement remains a hurdle. Learn why TEM stock is worth ...

Instead, the company is working on integrating the large acquisition of California-based Ambry Genetics. In June, Tempus said it employed about 2,300 people, many of them in Chicago. It has labs ...

Nancy Pelosi's newest bet saw the purchase of Tempus AI call options — now, a Wall Street analyst has given the stock a new ...